Analisis Minimalisasi Biaya Antibiotik Ceftriaxone dan Cefotaxime pada Pasien Pneumonia Dewasa Rawat Inap RSUDP NTB 2018

Autor:	Aulia Nabila, Candra Eka Puspitasari, G.A.P. Sri Erwinayanti
Rok vydání:	2021
Předmět:	medicine.medical_specialty Cefotaxime business.industry medicine.drug_class Drug cost Significant difference Cephalosporin Antibiotics medicine.disease Pneumonia Internal medicine Hospitalization cost medicine Ceftriaxone business health care economics and organizations medicine.drug
Zdroj:	Jurnal Sains dan Kesehatan. 3:72-78
ISSN:	2407-6082 2303-0267
DOI:	10.25026/jsk.v3i1.205
Popis:	Pneumonia is an infection on the lung tissue that caused the lung would not be able to work properly. The first-line choice of therapy in pneumonia is using cephalosporin class of antibiotic which are ceftriaxone and cefotaxime. Both of those therapies have significant difference in cost, so that a pharmaceconomic analysis needs to be done using the cost-minimization analysis (CMA) method. This research to analyze minimization cost of antibiotic ceftriaxone and cefotaxime in adult pneumonia patients with cured outcomes in inpatients at RSUD Provinsi NTB in 2018. The research was conducted from July to August 2019. The sampling technique in this research was total sampling with 18 samples. The data used is retrospective in 2018. Ceftriaxone and cefotaxime cost-minimization analysis using comparison of the total cost calculation showed that cefotaxime therapy is more cost-minimized Rp 1.297.829 or 26,1% than ceftriaxone therapy. There was a significant difference between hospitalization cost and drug cost for the ceftriaxone and cefotaxime drug groups using the t-Test with p < 0.05. Keywords : pneumonia, ceftriaxone, cefotaxime, cost-minimization analysis
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8a293d8e9e76f695ec607950b59ccab4 https://doi.org/10.25026/jsk.v3i1.205 Zobrazit plný text záznamu